SCHEMBL15636715

SCHEMBL15636715

O[C@H]1CC[C@@H](n2ccc3c(Cl)ncnc32)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2A P48426 1/20 0.45
PRMT5 O14744 11/20 0.43
WDR77 Q9BQA1 10/20 0.43
SLC22A12 Q96S37 1/20 0.39
CDC7 O00311 1/20 0.37
PLK4 O00444 1/20 0.37
DYRK3 O43781 1/20 0.37
JAK2 O60674 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
NTRK1 P04629 1/20 0.37
INSR P06213 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
CDK1 P06493 1/20 0.37
RET P07949 1/20 0.37
ROS1 P08922 1/20 0.37
SRC P12931 1/20 0.37
FER P16591 1/20 0.37
PRKACA P17612 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1442966 1.00 PIP4K2A (0.45) PIP4K2APRMT5WDR77SLC22A12CDC7
SCHEMBL1442965 1.00 PIP4K2A (0.45) PIP4K2APRMT5WDR77SLC22A12CDC7
SCHEMBL16967987 0.92 PIP4K2A (0.49) PIP4K2APRMT5WDR77SLC22A12SRC
SCHEMBL18571707 0.92 ABL1 (0.44) PIP4K2APRMT5WDR77SLC22A12CDC7
SCHEMBL16769947 0.87 PRMT5 (0.44) PIP4K2APRMT5WDR77SLC22A12NNMT
SCHEMBL24753099 0.86 PIP4K2A (0.44) PIP4K2APRMT5WDR77SLC22A12SRC
SCHEMBL1939828 0.86 PIP4K2A (0.44) PIP4K2APRMT5WDR77SLC22A12MAP4K4
SCHEMBL17877686 0.85 PIP4K2A (0.44) PIP4K2APRMT5WDR77SLC22A12MAP4K4
SCHEMBL1441891 0.85 PIP4K2A (0.42) PIP4K2APRMT5WDR77SLC22A12NNMT
SCHEMBL9950030 0.85 PIP4K2A (0.42) PIP4K2APRMT5WDR77SLC22A12NNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903989-A1 PYRROLO[2,3-D]PYRIMIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS Pfizer Limited (GB) 2015-08-12 EP disclosed
US-20150218172-A1 Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors PFIZER LIMITED (GB) 2015-08-06 US disclosed
US-20150218172-A1 Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors PFIZER LIMITED (GB) 2015-08-06 US disclosed
US-20150218172-A1 Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors PFIZER LIMITED (GB) 2015-08-06 US disclosed
WO-2014053967-A1 PYRROLO[2,3-D]PYRIMIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER LIMITED (GB) 2014-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218172-A1 Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors MUSK, DMPK, TPM3 PIP4K2A 364/4885PRMT5 817/4885WDR77 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.